Ivan Tornos: Thank you so very much. So starting with robots and capital dynamics, look, I will tell you one thing that is pretty prevalent is that here in the U.S., we’ve seen the cases move to the ASC. Not a week goes by that there’s not a new ASC opening and those ASCs do want to acquire robotics, and you either install or you purchase it. We saw a dynamic in Q1 where we saw more purchases. We do believe this is driven by ASC dynamics. Capital continues to be strong across key markets, so definitely not a gating factor. And, again, as I mentioned earlier, excited about the continuity here. In terms of your second question on M&A, look, we want to be bigger and bolder. At the same time, we’re not going to be reckless and we said that all along.
So we want to stick to the strategic and financial thresholds. We got the pipeline. We got the money. And when it’s time to act, we’ll act on it, and we’re not going to take the past as an indicator of how we’re going to do things in the present and future. The breakdown on the WinGuard, we’ll cover that as well once we get into the Investor Day, and it is a combination of organic and inorganic means. So we’ll talk about the pipeline. I already mentioned, we already mentioned that 80%, if not 90%, of the new products in the pipeline are in markets that are growing about 4%, in some cases about 5%. So that’s definitely a driver. And then the combination of tuck-in deals and maybe some bolder moves will get us to the WinGuard that we deserve.
So more to come in that regard. Thanks for the question.
Shagun Singh: Thank you.
Ivan Tornos: I think we’re coming to the end of the call. So I’m just going to briefly close with closing comments. I’ll start by saying that it’s great to be here at home in Warsaw, Indiana today to celebrate Founders Day. So May 2, 1927, we started a company with a very clear purpose, to alleviate pain and improve the quality of life for people around the world. So 97 years later, I just can say that we’re just getting started. So excited to see where we are as a company. It’s an exciting time to be at Zimmer Biomet and the portfolio is where it needs to be. We have a strong commercial execution. We are very, very confident on our guidance for the year 2024. We are excited about what’s to come in 2025 and 2026 once we’re able to discuss the long-range plan.
So nothing but confidence and excitement. Before closing, I want to thank Keri for four and a half great years with us. You’ve been a trusted partner, a great friend. You’re going to be missed, although I’m going to continue to call you and seek your advice many, many years to come. So thank you, Keri, and thanks everybody.
Keri Mattox: Thanks everyone for joining. We’ll be talking to all of you today. If you have questions, of course, please don’t hesitate to reach out to the IR team. Thank you again for joining the call this morning.
Operator: That will conclude today’s call. We appreciate your participation.
